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Abstract
Background: Malaria remains a critical public health problem in Southeast Asia despite intensive containment efforts.
The continued spread of multi-drug-resistant Plasmodium falciparum has led to calls for malaria elimination on the
Thai-Cambodian border. However, the optimal approach to elimination in difficult-to-reach border populations, such as
the Military, remains unclear.
Methods/design: A two-arm, cluster-randomized controlled, open-label pilot study is being conducted in military
personnel and their families at focal endemic areas on the Thai-Cambodian border. The primary objective is to
compare the effectiveness of monthly malaria prophylaxis (MMP) with dihydroartemisinin-piperaquine and weekly
primaquine for 12 weeks compared with focused screening and treating (FSAT) following current Cambodian national
treatment guidelines. Eight separate military encampments, making up approximately 1000 military personnel and their
families, undergo randomization to the MMP or FSAT intervention for 3 months, with an additional 3 months’ follow-
up. In addition, each treatment cluster of military personnel and civilians is also randomly assigned to receive either
permethrin- or sham (water)-treated clothing in single-blind fashion. The primary endpoint is risk reduction for malaria
infection in geographically distinct military encampments based on their treatment strategy. Monthly malaria screening
in both arms is done via microscopy, PCR, and rapid diagnostic testing to compare both the accuracy and cost-
effectiveness of diagnostic modalities to detect asymptomatic infection. Universal glucose-6-phosphate dehydrogenase
(G6PD) deficiency screening is done at entry, comparing the results from a commercially available rapid diagnostic test,
the fluorescence spot test, and quantitative testing for accuracy and cost-effectiveness. The comparative safety of the
interventions chosen is also being evaluated.
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Discussion: Despite the apparent urgency, the key operational elements of proposed malaria elimination strategies in
Southeast Asian mobile and migrant populations, including the Military, have yet to be rigorously tested in a well-
controlled clinical study. Here, we present a protocol for the primary evaluation of two treatment paradigms – monthly
malaria prophylaxis and focused screening and treatment – to achieve malaria elimination in a Cambodian military
population. We will also assess the feasibility and incremental benefit of outdoor-biting vector intervention –
permethrin-treated clothing. In the process, we aim to define the cost-effectiveness of the inputs required for success
including a responsive information system, skilled human resource and laboratory infrastructure requirements, and
quality management. Despite being a relatively low transmission area, the complexities of multi-drug-resistant malaria
and the movement of vulnerable populations require an approach that is not only technically sound, but simple
enough to be achievable.
Trial registration: ClinicalTrials.gov, ID: NCT02653898. Registered on 13 January 2016.
Keywords: Malaria, Elimination, Cambodia, Dihydroartemisinin-piperaquine, Primaquine, Permethrin, Mass drug
administration,
Background
Malaria remains a scourge to humankind with 270 million
cases and over 600,000 deaths annually [1]. Despite inten-
sive containment and control efforts, multi-drug-resistant
(MDR) Plasmodium falciparum continues to be endemic
in border areas of Cambodia. Over the last several years,
reports have highlighted the declining efficacy of artemisi-
nin combination therapies (ACT) within a few years of
their introduction as first-line therapies [2–5]. As P. falcip-
arum outpaces the development of efficacious antimalarial
drugs, the focus has shifted to elimination of MDR mal-
aria on the Thai-Cambodian border [4]. While the current
means available to eliminate malaria are admittedly imper-
fect, waiting to act may result in a setback to recent gains
in malaria control because of the increasingly rapid spread
of resistance of P. falciparum and fewer treatment options
being available [6].
To prevent the spread of multi-drug-resistant malaria,
elimination is now being widely advocated in Cambodia,
particularly in hard-to-reach mobile and migrant popu-
lations including the Military, an under-recognized res-
ervoir of disease [2, 7]. Elimination of MDR malaria at
the Thai-Cambodian border is critical given its transient
populations who have the highest incidence of malaria
in the Greater Mekong Subregion (GMS) [8, 9]. Harnes-
sing the Military’s organizational capacity has recently
been proposed as a novel strategy to effectively carry out
malaria elimination programs in other more vulnerable
mobile groups in close proximity along the borders [10,
11]. Such a strategy could be feasibly scaled as part of a
national campaign, leveraging military infrastructure and
organizational capacity, and emulated by other regional
militaries in the GMS if successful.
However, the question remains: to effectively eliminate
malaria in these populations, what are the optimal inter-
ventions? A potentially large, but as yet poorly defined,
group of asymptomatic parasitemic persons poses a
particular challenge to identifying the at-risk population
[12–14]. Though more recent data in Cambodia suggests
otherwise [15, 16], it has been presumed that submicro-
scopic asymptomatic parasitemias contribute signifi-
cantly to ongoing transmission and thus constitute an
infectious reservoir that must be addressed in
low-endemic settings to achieve elimination [15, 17, 18].
If molecular diagnostic testing is needed to identify per-
sons in this reservoir, or if medical follow-up require-
ments are too intense to support, large-scale
implementation may be difficult or impossible in aus-
tere, remote locations. This conclusion has also been
suggested by focused screen-and-treat programs as well
as reactive case detection strategies in low-transmission
areas of Cambodia in civilian populations [19–21].
Unfortunately, the only licensed, available drug able to
prevent transmission of the parasite from human to mos-
quito, primaquine (PQ), can cause severe, life-threatening
hemolytic anemia in persons with glucose-6-phosphate
dehydrogenase (G6PD) deficiency, and requires effective
screening tests that can be easily deployed at the point of
care. To permit the greatest possible simplicity and
cost-effectiveness during scale-up in resource-poor areas
along the border, the ideal approach would require min-
imal medical monitoring or follow-up visits. Suitability for
scale-up will also need to be assessed for operational feasi-
bility, perception of risk among participants, cost and
cost-effectiveness of interventions, and alignment with
stakeholder values and policy.
Aim and objectives
We present a pilot operational research protocol to in-
vestigate the effectiveness of monthly prophylactic drug
administration compared to a focused screen-and-treat
approach to inform a regional malaria elimination initia-
tive by the Royal Cambodian Armed Forces (RCAF).
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 Primary objective: to compare the effectiveness of
focused screening and treatment (FSAT) following
current national treatment guidelines versus monthly
malaria prophylaxis (MMP) with dihydroartemisinin-
piperaquine (DHA-PIP) in combination with weekly
primaquine (PQ) (22.5 mg) as transmission-blocking
and radical curative agent to reduce the risk of malaria
infection in personnel residing in military encamp-
ments on the Thai-Cambodian border
 Secondary objectives:
◦ To estimate the incremental benefit of wearing a
permethrin insecticide-treated uniform (ITU) over
drug therapy and existing vector control
interventions compared to a sham insecticide-
treated uniform (sITU) treated with water. Civilian
participants will have comparable selected outer
garments treated
◦ To define the proportion of asymptomatic
carriers of malaria in the population, including the
cumulative incidence and incidence density of
microscopic and submicroscopic blood-stage para-
sitemia and gametocytemia
◦ Additional secondary objectives can be found in
Table 1/Additional file 1
Lastly, an overarching aim of this operational study is
to increase The Cambodian Military’s capability to diag-
nose, prevent, and treat malaria, and to understand the
population’s willingness to participate in malaria elimin-
ation campaigns. To do so, a scalable military malaria
elimination “unit of action” is being established at the
provincial level, staffed by RCAF personnel who are
trained during the course of this study. Regardless of the
outcome, the study will provide critically important
Table 1 Outcomes
Objectives Outcomes/endpoints
Primary
To compare the effectiveness of focused screening and treatment
(FSAT) following current national treatment guidelines versus
targeted monthly malaria prophylaxis (MMP) with DHA-piperaquine
in combination with low-dose weekly primaquine (PQ) (22.5 mg)
for 12 weeks
Absolute risk reduction in a cluster based on those individuals’ polymerase
chain reaction (PCR)-corrected absence of parasitemia at the end of 6
months in the MMP versus FSAT clusters
Secondary
Estimate the incremental benefit of insecticide-treated uniforms (ITU)
over drug therapy and existing vector control interventions compared
to a sham insecticide-treated uniform (sITU)a
Absolute risk reduction in a cluster based on those individuals’
PCR-corrected absence of parasitemia at the end of 6 monthsa
Proportional landings of mosquitoes on treated uniform’s swatch
side of cages
Assess the effectiveness of presumptive anti-relapse and
transmission-blocking therapy with weekly low-dose
primaquine (22.5 mg)a
Incidence of P. vivax recurrent infection and PCR-corrected P. falciparum
recrudescencea
PCR-corrected absence of gametocytemiaa
Evaluate the safety and tolerability of blood-stage antimalarials and
weekly low-dose primaquine at 12 weeks versus 8 weeks in treated
MMP and FSAT volunteers, respectively
Number of hemolytic events or other serious adverse events in
participants over 13 years of age receiving primaquine
Assess level of antimalarial drug resistance at the selected study sites Number of all-species malaria recurrence, established molecular markers
of drug resistance, and clinical failure rates based on WHO criteria
Define the proportion of asymptomatic carriers of malaria in the
study population
Cumulative incidence and incidence density of PCR-corrected parasitemia
and submicroscopic parasitemia in each arm
Define the epidemiology of malaria infection in volunteers
developing malaria
Cumulative incidence and incidence density of parasitemia
Compare the sensitivity and specificity of the currently recommended
malaria rapid diagnostic test of choice in Cambodia with RT-PCR
Retrospective assessment of the proportion of asymptomatic carriers that
would have been missed by each test and an estimate of the incremental
cost-effectiveness of each test
Compare sensitivity and specificity of two currently available rapid
diagnostic tests to detect moderate to severe G6PD deficiency
using quantitative G6PD testing as the reference standard
Retrospective assessment of the proportion of persons with moderate to
severe deficiency who would have been missed with each screening
modality, and an estimate of the cost-effectiveness of each test
Describe population demographics to include the acceptability of
FSAT, malaria prophylaxis, and use of vector control measures
among participants, including willingness to participate in future
malaria elimination campaigns
Descriptive analysis of participants’ responses to survey questions pre and
post study regarding FSAT, malaria prophylaxis, and use of vector control
measures
Support host nation capabilities by improving the Royal Cambodian
Armed Forces’ (RCAF’s) ability to diagnose, prevent, and treat malaria
supported by robust data to achieve malaria elimination
A scalable military malaria elimination “unit of action” will be established
at the provincial level, staffed by RCAF personnel trained during the
course of the study
aPilot study objective and endpoint added to assess operational feasibility given ongoing community concerns regarding these interventions. These endpoints are
statistically underpowered and this data will be used to inform larger studies in the future
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information to inform elimination policy in Cambodia
and the GMS.
Methods/design
Study design
We are conducting a two-arm, cluster-randomized,
open-label controlled trial of MMP with t3-day DHA-PIP
and weekly PQ compared to focused screening and treat-
ing (FSAT) following current national treatment guide-
lines. Participants in the MMP arm receive a monthly
3-day course of fixed-combination tablet containing
40 mg of dihydroartemisinin and 320 mg of piperaquine
phosphate for three consecutive months. Those aged
13 years and older receive low-dose weekly PQ (22.5 mg)
therapy to prevent malaria transmission for 12 weeks.
Participants in the FSAT arm are screened with highly
sensitive polymerase chain reaction (PCR) methods, and
all those testing positive for malaria receive therapy with
first-line antimalarials following current national treat-
ment guidelines. At the time of protocol development,
artesunate-mefloquine combination therapy is the
first-line treatment for P. falciparum in provinces with
known antimalarial resistance, with a single, low dose of
PQ (15 mg) to prevent malaria transmission. For partici-
pants in the FSAT arm with Plasmodium vivax malaria,
the recommended treatment for asexual parasitemia is
DHA-PIP. All patients with P. vivax in the FSAT arm
receive treatment with 15 mg of PQ daily for 14 days if
G6PD normal, or 45 mg weekly if G6PD deficient.
Study site and population
The study takes place at multiple military encampments
in malaria-endemic areas in border areas authorized by
the Ministry of National Defense. Sites were chosen based
on current malaria incidence estimates by the RCAF
health services in consultation with the National Center
for Parasitology, Entomology, and Malaria Control (CNM)
in Cambodia and the Armed Forces Research Institute of
Medical Sciences (AFRIMS). For reasons of operational
security, locations or other descriptors will not be further
described here. All sites will be evaluated as simultan-
eously as feasibly possible.
Military volunteers aged 18–65 years of age and their
dependents of ≥ 2 years of age, eligible for care at an RCAF
facility, or otherwise eligible Cambodian civilians at risk for
contracting malaria who live within close proximity, are
enrolled if they meet the following criteria: are able to give
informed consent/assent; reside in the selected study areas;
are available for monthly follow-up for 6 months; agree not
to seek outside medical care for febrile illness unless
referred by study team; and are authorized by respective
military unit commanders to participate in the study if on
active duty. Volunteers who have known allergy or other
contraindication to study medication; are pregnant,
lactating or are women of childbearing age who do not
agree to use an acceptable form of contraception during
the study; or are judged by the investigator to be otherwise
unsuitable for study participation are excluded from the
study.
Cluster randomization, allocation, and blinding
Geographical areas were randomized prior to study start to
a 1:1 allocation of MMP or FSAT using time- and
region-blocked randomization to ensure that
randomization is geographically distinct, and that malaria
incidence is evenly distributed among groups given that
high and low transmission areas exist. Volunteers meeting
the enrollment criteria receive permethrin- or sham-treated
(water-treated) uniforms according to their cluster’s assign-
ment in single-blind fashion (volunteer blinded to assign-
ment but not investigator). Entomology staff conducting
uniform testing are also blinded to treatment. Diagnostic
microscopists are blinded to each others’ readings and to
study arm assignment. There is otherwise no blinding
during the study.
Treatment intervention
Volunteers randomized to MMP arm aged 13 years and
older receive a monthly 3-day treatment course of (DHA--
PIP; 360/2880 mg) for 3 months. They will also receive a
weekly dose of 22.5 mg of PQ for 12 weeks. Children of 12
years of age or less will receive only a monthly 3-day
weight-based treatment dose of DP for 3 months without
PQ treatment. In the MMP arm, symptomatic patients or
microscopy-confirmed parasitemia in the first 3 months
are considered a failure of prophylaxis and treatment is
given according to the national treatment guidelines. If the
volunteer has parasitemia detectable by PCR only and is
symptom free at monthly follow-up, the study treatment
with monthly DHA-PIP is continued for 3 months as
outlined for the MMP arm. To reduce phlebotomy require-
ments for G6PD testing and potential hemolytic risk in
children, PQ is not be administered to those less than
13 years old.
Volunteers randomized to the focused screening and
treatment (FSAT) arm are treated according to current
national malaria treatment guidelines if they test positive
for malaria based on blood smear and/or real-time PCR
results during monthly follow-up. In the FSAT arm, all
volunteers with parasitemia detectable with PCR receive
antimalarial treatment, even if they are symptom- free.
At the time of protocol development, national treatment
guidelines for areas of known piperaquine resistance, to
include the designated study regions, recommended a
3-day course of artesunate and mefloquine (A +M) and a
single 15-mg dose of PQ for acute P. falciparum, or DP
for blood-stage P. vivax infection. Elimination interven-
tions are carried out monthly during the first 3 months
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after enrollment, and then followed by 3 months of add-
itional malaria assessment by smear and PCR diagnosis
with malaria treatment as necessary following current na-
tional treatment guidelines (Fig. 1, Table 2, Fig. 2). Those
febrile but negative for malaria are referred for evaluation
and treatment of alternative diagnoses.
Clinical procedures
Following documentation of informed consent/assent and
determination of eligibility, a study physician completes an
initial medical history and physical examination (Table 2).
Volunteers aged 13 years and older have a rapid diagnostic
test (RDT) for malaria, thick and thin blood films to esti-
mate both sexual and asexual parasite densities, and mal-
aria PCR diagnosis. Additional laboratory testing includes a
complete blood count (CBC); an estimate of G6PD activity
using quantitative testing to be compared with fluores-
cence and commercially available point-of-care testing;
G6PD genotyping; real-time PCR to detect gametocytes;
and analysis of molecular markers of resistance for those
malaria positive at intake. Children aged 12 years and
under have only rapid malaria diagnostic testing, malaria
smears and PCR to detect submicroscopic parasitemia,
with other testing deferred in children to reduce phlebot-
omy burden. Children less than 13 years of age are not
tested for G6PD deficiency as they are not treated with PQ
under this protocol. G6PD-deficient volunteers 13 years
and older are counseled regarding the diagnosis, and have
a repeat CBC on day 3 (± 1 day) following PQ treatment
with repeat testing on day 7, if they have a greater than
10% drop in their hemoglobin or hematocrit, or at any time
there are clinical signs of hemolysis.
All volunteers are followed monthly thereafter or at any
time that they present with symptoms of suspected
malaria, with a brief clinical evaluation and malaria
diagnostics to include PCR assays for asexual and sexual
parasites. Malaria-positive volunteers aged 13 years and
older have additional tests for molecular markers of resist-
ance. At these times, a swatch is taken from the volun-
teer’s uniform or clothing for repellency monitoring.
Fig. 1 Study flow diagram
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Table 2 Table of times and events for adults and children over 12 years of age
Event Screen/enroll
day 1
Day 33 Day 307 Day 607 Day 907 Day 1207 Day 1507 Day 1807 Malaria diagnosis/
recurrence2
a. Informed consent X
b. Medical history X
c. Physical exam X X
d. Brief clinical evaluation
and vital signs1
X X X X X X X
e. Malaria RDT, DBS, smear
and PCR genotyping6
2 mL 1.5 1.5 1.5 1.5 1.5 1.5 1.5 mL
i. CBC 1 mL 1 mL3
k. Molecular resistance
markers2
6 mL
l. G6PD RDT, fluorescent
spot, quantitative testing
1.5 mL
m. Gametocyte PCR 2.5 mL 2.5 2.5 2.5 2.5 2.5 2.5 2.5 mL
n. Urine pregnancy test
(women of child-bearing
age)
X X X X
o. Malaria treatment4,5 X X X X
Daily phlebotomy (mL) 7 13 4 4 4 4 4 4 10
Cumulative phlebotomy (approximately mL) 7 11 15 19 23 27 31 41
1Brief clinical evaluation includes an interval medical history, vital signs and a directed physical exam as indicated
2Performed only for volunteers with smear-positive malaria. Those with PCR-positive malaria will be treated following national guidelines but will not have blood
drawn for molecular markers of resistance
3To be drawn for G6PD-deficient volunteers only. All G6PD-deficient volunteers with > 10% of Hgb or HTC drop on D3 will have CBC on day 7
4Patients screening positive on microscopy and/or PCR for P. falciparum malaria in the FSAT arm will receive currently recommended blood-stage antimalarials
under published national treatment guidelines as well as single, low-dose primaquine (15 mg). Volunteers with P. vivax will be treated with the currently
recommended blood-stage agent (DHA-PIP), as well as primaquine – G6PD-normal volunteers will receive 15 mg daily for 14 days, while G6PD-deficient volunteer
will receive 45 mg × 8 weeks. All volunteers in the MMP arm will receive a fixed-dose 3-day course of DHA-piperaquine at 0, 24 and 48 h starting on days 1, 30,
and 60, and a weekly 22.5-mg dose of primaquine for 12 weeks. All therapy will be directly observed
5For all volunteers with recurrent malaria, rescue therapy will be with the recommended agent(s) per national guidelines
6May be repeated as medically indicated (e.g., if patient is malaria-positive or otherwise ill on enrollment). An additional 0.5 mL will be collected on the day of
enrollment for baseline G6PD genotyping
7Time window of ± 7 days
CBC complete blood count, DBS dried blood spot, DHA-PIP dihydroartemisinin-piperaquine, G6PD glucose-6-phosphatase dehydrogenase, Hgb hemoglobin, PCR
polymerase chain reaction, RDT rapid diagnostic test
Fig. 2. Study timeline for monthly malaria prophylaxis (MMP) intervention clusters. *Treat with artesunate and mefloquine. DHA-PIP
dihydroartemisinin-piperaquine, GC gametocyte, RDT rapid diagnostic test, PCR polymerase chain reaction, G6PD glucose-6-phosphatase
dehydrogenase, CBC complete blood count
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At the conclusion of the 180-day (− 2 to + 3 days)
follow-up period, volunteers have blood drawn for malaria
smears, RDTs, asexual blood-stage and gametocyte PCR
diagnosis. If infection is noted at discharge, volunteers will
continue to be followed until resolution of infection.
Laboratory procedures
Microscopy
Stained thick and thin blood smears are examined by two
microscopists blinded to each other’s results and to the
treatment status of the study volunteer. Two blood smears
are made for every enrolled volunteer. Slide 1 is stained
immediately and examination of Giemsa-stained thick and
thin smears made. This slide is stored in a different box
from slide 2, which is only read if there is a problem with
the first slide.
Parasite densities are calculated based on a count of
parasites per 200 white blood cells (WBCs) (thick film)
or for low parasitemias (e.g., 10 parasites/μL), per 500
WBC or 5000 red blood cells (RBCs) (thin film). Both
asexual and sexual stages are enumerated. A total of 200
oil immersion fields are examined on the thick film
before a blood smear is considered negative. The final
count is determined by taking the geometric mean of
the two counts. In case of a difference in results
(positive/negative; species diagnosis) between the two
microscopists, the blood smear is re-examined by a third
microscopist blinded to the results of the first two
readers and the treatment regimen, and the third read-
ing is accepted as the final result.
Malaria microscopy results is confirmed using
real-time PCR correction for the detection of P. falcip-
arum and P. vivax using 18S ribosomal ribonucleic acid
(RNA) (18S rRNA) genes unique to each species. Para-
site deoxyribonucleic acid (DNA) will be isolated from
approximately 200–250 μL of venous or capillary blood
collected in an EDTA microtube.
PCR genotyping
One milliliter of blood is drawn on day 1 if malaria-posi-
tive and at recurrence. PCR genotyping of msp1, msp2,
and GLURP genes is performed to identify the unique fin-
gerprint of the infecting parasite and any subsequent de-
velopment of malaria after therapy in order to determine
if it is a recrudescent infection or new infecting genotype
[22]. Gametocyte PCR and molecular marker analysis is
performed as previously described [23–26].
G6PD testing
On enrollment, volunteers are assessed for G6PD defi-
ciency with both fluorescence (qualitative) and quantita-
tive testing, and one or more commercially available
point-of-care test kits, and correlated with single nucleo-
tide polymorphism analysis for G6PD gene mutations.
Approximately 1.5 mL per blood draw is collected in an
EDTA (anticoagulant) tube for this purpose.
Venous blood is tested for qualitative G6PD activity
using the fluorescent spot test method, as recommended
by the International Committee for Standardization in
Hematology using commercially available kits (R&D
Diagnostics Ltd., Greece). This method detects fluores-
cence of the enzyme NADPH under long-wave (365 nm)
UV light. Reduction of NADP to NADPH occurs in the
presence of G6PD. The rate and extent of NADPH
formation is proportional to G6PD activity. Normal
samples fluoresce brightly, whereas deficient samples
show little or no fluorescence [2].
Quantitative testing will be performed using an
FDA-approved test kit (e.g., Trinity Biotech, Ireland) and
results will be calculated based on same-day hemoglobin
values from the CBC. Severe deficiency (WHO class I or
II) will be defined as 10% or less of the lower limit of
normal activity (in G6PD activity units per gram of
hemoglobin) established for the quantitative assay sys-
tem. Subjects with severe deficiency will be enrolled in
the study as this is not an exclusion criterion; class I–V
deficiencies are permissible for enrollment. To evaluate
the performance of a commercial G6PD deficiency RDT
in malaria patients from Cambodia, the CareStart™
G6PD test is being compared to the “gold standard”
G6PD enzyme quantitative test for their potential use as
point-of-care diagnostics for G6PD deficiency. However,
no clinical decisions will be made based on the results of
either point-of-care test in this study.
Permethrin clothing treatment
Each uniform is treated by study staff according to the
site’s randomization prior to distribution with a single
application of the 40% permethrin Individual Dynamic
Absorption (IDA) kit from the US Army’s supply system
or water only for sham-treated uniforms. Permethrin
treatment is designed to last for 30 washings, which
should be suitable for the 6-month duration of the study.
At enrollment, each volunteer has one to two field
uniforms treated, and civilian volunteers have one to
two sets of outer covering garments that they wear while
in forested areas treated. The number of clothing sets
treated will depend on the number in the volunteer’s
possession, and additional clothing sets may be treated
during the course of the study if/when the volunteer
acquires new clothing, or when treated clothing is
damaged or becomes otherwise unserviceable.
Monitoring of treated uniform repellency will be per-
formed by taking uniform swatches numbered with the
subject’s study ID at monthly intervals for 6 months.
The numbered swatches will be sewn into the uniforms
at the time of treatment. Blinded entomology techni-
cians will randomly select 5% of uniform swatches, and
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place them in cages of female mosquitoes to observe for
repellency. The clothing swatches will be placed on the
wall of the mosquito cages and proportional landings on
the swatch side of the cage will be assessed.
Sample size rationale
Up to 1200 persons are being enrolled and followed in
this cluster-randomized study. The study compares esti-
mates of the absolute risk reduction based on the pro-
portion remaining malaria free at the end of 6 months.
We assume that MMP administration combined with an
insecticide-treated uniform (ITU) on the background of
any pre-existing vector control methods that might be
employed will need to reduce malaria incidence to zero
by study conclusion to achieve elimination. The MMP
approach will be using nearly every currently available
intervention in Cambodia to eliminate malaria in this
population. Current mathematical models show that
multi-round mass drug administration (MDA) can re-
duce malaria prevalence to less than 10% if high cover-
age is achieved [27]. Focused screening and treatment
alone (FSAT) is assumed to be 50% effective based on a
recent study at the same site which found that only 50%
of patients treated using an intense screening and treat-
ment approach remained malaria free at the end of 4–
6 months of follow-up [2]. The study is, therefore, pow-
ered to detect a two-fold difference in effectiveness be-
tween the two intervention groups. These are thought to
be reasonable assumptions a priori for the purposes of
sample size calculations though there has never been a
head-to-head comparison of these strategies published in
the literature. Given that this will be a stratified analysis, no
assumptions regarding vector control measures are in-
cluded in the calculation. Pre-existing vector control mea-
sures that the Military may employ, including ITNs, are
assumed to be equally distributed among the overall study
population. Permethrin-treated uniform comparisons are a
secondary endpoint intended only to estimate a potential
additive effect.
Because observations of individuals in the same geo-
graphical area (e.g., cluster) are correlated (non-indepen-
dent), the effective sample size needed is larger than an
individualized randomized trial. Given that the intracor-
relation coefficient (ICC) is not known, we assumed a
conservative value of 0.4. To detect a minimum of a
two-fold difference in the effectiveness of MDA over
FSAT in proportion of volunteers being malaria-free at
6 months with an α = 0.05 and 80% power, the number
needed in each cluster is at least 78 individuals [28].
Given that the number of clusters is limited based on
RCAF organization and patrolling areas, our proposed
cluster number of 8 with a size of 80–140 volunteers per
cluster would be sufficient even at higher (e.g., more
conservative) values of ICC (> 0.4).
Statistical methods
The primary study endpoint will be the absolute risk re-
duction (ARR) with 95% confidence intervals (CIs) based
on the proportion of volunteers in each arm with absence
of PCR-positive parasitemia at the end of 6 months using
an intention-to-treat analysis (Table 1). In addition, logis-
tic regression modeling may be employed to provide
multivariate analyses based on other possible study con-
founders such as age, proportion of children, proportion
of pregnant women, etc. The primary study population
will be intention-to-treat, defined as all volunteers (both
military and civilian family members) who are enrolled at
either site. The per-protocol analysis population will in-
clude all those volunteers who enrolled and completed
follow-up up to 180 days. However, volunteers lost to
follow-up that do not complete up to 180 days of
follow-up will be excluded from the per-protocol analysis,
but included in an intention-to-treat analysis.
Secondary study endpoints are pilot endpoints to include
incidence rates, molecular and parasitological endpoints,
safety, vector control effectiveness (e.g., permethrin-treated
versus water-treated uniforms), and comparison of malaria
and G6PD diagnostic modalities. The calculation of inci-
dence rates (attack rate over total time at risk) for prophy-
lactic and FSAT groups will be calculated adjusted and
unadjusted with 95% CI. All volunteers completing at least
one follow-up assessment will be included in the safety
analysis. The safety analysis database will include those vol-
unteers in the set of randomized volunteers who receive at
least one dose of study drug. All parasitological data will be
included in the parasitological analyses. A stratified analysis
comparing the vector control arms within each group will
also be compared as those remaining malaria-free at
180 days. Given the possibility of the highly variable nature
of transmission at the geographical sites, existing pre-en-
rollment malaria surveillance data by RCAF and day 1
screening data by AFRIMS will guide if a pair-matched
analysis is necessary.
Halting rules criteria
Any volunteer with G6PD deficiency who experiences
grade 3 hemolysis following PQ administration will be
discontinued from the use of PQ and monitored closely.
If more than three subjects with G6PD deficiency are
found to have grade 3 hemolysis following treatment
with PQ for anti-relapse therapy, further treatment with
PQ will be suspended for all G6PD-deficient subjects en-
rolled in the study.
Data storage and handling
Clinical and laboratory data pertaining to drug efficacy
are collected and managed by AFRIMS Immunology and
Medicine staff and RCAF personnel. All data and
medical information obtained from study volunteers are
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considered privileged and confidential. Volunteers enrol-
ling in the study are issued a unique identification code
(UIC), which is used on all study files and clinical sam-
ple labels. Individually identifiable volunteer information
other than the UIC are not transcribed on other study
documents to include laboratory sample labels, case
report forms, nor included in the presentation of study
results. Data is double-entered into a Microsoft Access
database (Microsoft Corp) with source data verification
for each entry.
Ethical approval
This trial has been approved by the Walter Reed Army
Institute of Research (WRAIR) and the National Ethical
Committee for Health Research (NECHR) in Cambodia.
Discussion
Overall rationale for the study
Elimination of malaria in mobile and migrant popula-
tions in border areas is of increasing importance as
these transient populations carry a significant amount
of MDR malaria burden in the GMS [8, 29, 30]. Des-
pite the apparent urgency and attention to defining
Southeast Asian mobile and migrant populations [31],
the key operational elements of proposed malaria
elimination strategies in these groups have yet to be
rigorously tested in a well-controlled clinical study.
This operational study protocol aims to define the
most effective and reproducible components of a mal-
aria elimination program specifically among Cambo-
dian military forces. While the choice of approach
and clinical regimen are important and oft-debated,
the underlying premise of the present study is that
the active engagement of military forces is likely to
have a far reaching impact on overall elimination ef-
forts. The sheer size, reach, and logistical capabilities
of military forces leave them ideally suited to conduct
large-scale elimination campaigns [11]. In that sense,
the study also serves as a real-life training exercise
for Cambodia’s military forces to develop needed cap-
acities to manage malaria elimination efforts. The
challenges of conducting a well-controlled elimination
study are the same as those of conducting malaria
elimination itself. Activities must be carefully coordi-
nated by health workers trained in the use of exacting
standard operating procedures and documented flaw-
lessly. Functioning laboratories capable of maintaining
high-quality control standards must be established.
Much like military campaigns, these intensive efforts
must be sustained for months or years. On all of
these counts, the present study serves as the ideal
training ground to build capacity and the skilled
workforce that will be needed for Cambodia to scale
up rigorous elimination efforts.
Challenges in malaria elimination
While terms describing “mobile populations” are often used
in reference to malaria elimination, they remain poorly de-
fined, and encompass a wide range of persons including
economic migrants, ethnic minorities, military and other
government personnel, and tourists. Mobility among mal-
aria endemic areas is their common shared trait, and for
the most part, their mobility makes them more difficult to
study. In this regard, military and government personnel
may be the easiest of these varied groups to study because
of the ability to provide comprehensive malaria prevention
and treatment services reliably despite frequent movement.
Military organization and chain of command provide fre-
quent opportunities for structured intervention, suggesting
that militaries may be among the easiest mobile groups to
achieve early malaria elimination. Despite these advantages,
the need to preserve operational and information security
and the need to ensure that research does not interfere with
the imperatives of military service remain important
barriers. The Military is also considered a vulnerable popu-
lation for medical research, and additional steps must be
taken to ensure that study participation is never coerced
through the chain of command. Potential transmission be-
tween surrounding communities and frequent personnel
movements are additional challenges in designing interven-
tions and assessing results [11].
Comparison of MMP versus FSAT, and problems with the
term “MDA”
The study is effectively comparing a large-scale malaria
prophylaxis approach using currently available interven-
tions with a more systematic version of current public
health efforts to identify and treat infected persons. The
primary objective of this study is to directly compare the
effectiveness of MMP with DHA-PIP and weekly PQ
against an active screening and treatment strategy fol-
lowing the current national malaria treatment guidelines.
In the province where the study was conducted at the
time of study inception, these included artesunate and
mefloquine combination treatment for all acutely in-
fected persons with P. falciparum malaria and DHA-PIP
for P. vivax malaria. While PQ use – either single-dose
for P. falciparum transmission-blocking or 14-day
anti-relapse therapy for P. vivax infections – is currently
advocated by treatment guidelines, implementation has
been limited and use officially restricted to facilities able
to screen for G6PD deficiency, greatly limiting applica-
tion outside controlled research studies. Perhaps more
important is the question of which, if any of the drugs
involved can be safely administered on a large scale, with
minimal or no medical supervision. Such practice,
termed “mass drug administration,” is often considered
as a means to treat significant numbers of infected indi-
viduals in limited-resource settings [32]. Because this
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term can be misconstrued, we have termed the key study
intervention “malaria prophylaxis” rather than “mass
drug administration” – the purpose is not merely to
eradicate malaria within the individual, but to protect all
treated individuals and their compatriots, treated and
untreated, from the collective threat of malaria transmis-
sion. While blood-stage agents, such as A +M and
DHA-piperaquine, achieve the former, only PQ adminis-
tration has been shown to treat mature gametocytes
responsible for mosquito transmission [33].
Selection of safe, effective prophylaxis from a dearth of
options
Selection of appropriate chemoprophylaxis requires a safe,
tolerable, and effective drug that can be administered
widely in the population. Such options, limited to begin
with, are rapidly dwindling in the GMS as MDR malaria
continues to gain a greater foothold [6]. The investigators
selected DHA-PIP despite recent reports of declining treat-
ment efficacy [3], though this was by no means a straight-
forward decision. Factors favoring its use included
prophylaxis studies demonstrating efficacy of monthly ad-
ministration of full DHA-PIP treatment courses in settings
of known MDR malaria [34–36]. DHA-PIP remains inex-
pensive and very well-tolerated with an excellent safety pro-
file, making it an ideal candidate for widespread
administration [37, 38]. QT-interval prolongation is a
known effect of piperaquine administration, though the
clinical significance remains unclear, and limited data sug-
gests reduced risk with a standard 3-day course of therapy
[39]. Atovaquone-proguanil was also considered, but given
its expense, daily administration and potential for rapidly
developing resistance, the requirement for directly observed
therapy (DOT) and strict follow-up would be difficult to
scale up. Furthermore, mathematical modeling suggests
that atovaquone-proguanil for MDA would result in further
spread of resistance with only temporary returns in elimin-
ation of malaria [40]. Lastly, a newer ACT,
pyronaridine-artesunate has been found to be
well-tolerated and non-inferior to artemether-lumenfan-
trine and artesunate-mefloquine, but limited safety data
precludes its use for an elimination campaign [41–43].
Though far from ideal, DHA-piperaquine was selected as
the least unfavorable of currently available options in order
to make current progress toward elimination rather than
await alternatives. Though its efficacy has plummeted
below accepted thresholds for treatment of acute P. falcip-
arum infection, it is likely to retain efficacy against subclin-
ical P. falciparum encountered in pre-elimination settings,
and P. vivax infections [2, 3, 13, 44].
Primaquine and transmission-blocking therapies
While considered an essential component for malaria
elimination [45–47], the safety of PQ must be given
careful consideration given the risk of hemolysis in
G6PD-deficient individuals, who may be at even more risk
in a large-scale elimination campaign that does not allow
for close, individual follow-up [48]. Grimmond et al. dem-
onstrated safe use of 22.5 mg of PQ weekly in combin-
ation with chloroquine for 8 weeks to prevent P. vivax
relapse in a cohort of Southeast Asian refugees in
Australia in 1984 [49]. This work and other more recent
dose-ranging studies informed selection of PQ dosing in
the present study [45, 49]. Risks of PQ administration
have been further mitigated in the study with extensive
G6PD screening using three modalities (rapid test, qualita-
tive, and quantitative testing) on individuals aged 13 years
and over who will receive PQ. Data generated by the study
will be highly informative for defining the minimum diag-
nostic G6PD-deficiency screening requirements to deliver
a safe and effective elimination program nationally.
Vector interventions
Another component of the study is designed to measure
whether using permethrin-treated clothing provides add-
itional protection against malaria infection. The incremen-
tal benefit of an oft-proposed outdoor-biting vector
intervention – permethrin-treated clothing – will be
assessed. The results of limited prior clinical evidence sug-
gested mixed outcomes. The intent of the present study is
to evaluate potential additive benefits of permethrin-treated
uniforms over the primary pharmacological interventions.
Evidence for effectiveness of permethrin-treated clothing is
largely limited to entomological studies given the scarcity of
controlled clinical trials evaluating disease outcomes [50].
While the RCAF already provide long-lasting
insecticide-treated nets (LLINs) to their soldiers, the effect-
iveness of this approach is unclear. The majority of
malaria-transmitting mosquitoes in the region are thought
to be outdoor, day-biting species although considerable het-
erogeneity in biting behaviors has been observed [51, 52].
Three small randomized, placebo-controlled studies of
insecticide-treated clothing have demonstrated protection
from malaria in similar settings, [50, 53, 54], but it remains
unclear whether previous results showing benefit can be
reproduced in the GMS, and if permethrin treatment is
cost-effective. Additional vector control modalities, such as
indoor residual spraying (IRS) and skin repellants, will not
be included in the present study given the added expense
of interventions, the nature of military service (mostly con-
ducted outdoors), and the lack of added benefit demon-
strated in areas with already high ITN coverage [55, 56].
Limitations
In the present pilot study it is necessary to make trade-offs
between complete rigor in statistical calculations in order
to conduct the study among military personnel actively
guarding a national border and their families. The study
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protocol aims not only to assess the comparative clin-
ical effectiveness of MMP versus FSAT interventions
(the primary objective), but also the practical feasibil-
ity of conducting intensive interventions at scale. A
key deliverable to public health authorities will be a
candid assessment of the degree to which competing
elimination strategies (e.g., MMP versus FSAT effect-
iveness) could be achieved with limited medical
supervision and safety monitoring in the field. As a
result, clinical effectiveness and practical feasibility
will be equally important outcome measures to deter-
mine next steps. It will be an ongoing challenge to
conduct well-controlled studies in austere border
areas, let alone rigorous elimination efforts. The study
protocol design is logistically constrained by virtue of
being primarily conducted in an active duty military
population. The practical limits imposed on the num-
ber of clusters available, and finite follow-up periods
are functions of the potential impact of the study on
availability of RCAF personnel. While the limited
number of clusters may effectively reduce power to
draw definitive conclusions from the study, we ac-
cepted this compromise in order to assess operational
feasibility. A randomized study of geographically iso-
lated clusters also risks disease transmission from sur-
rounding inhabitants and those choosing not to enroll
in the study. This is another accepted risk. Because
the present study cannot be confused with a public
health directive by the government, it will be uneth-
ical to compel any inhabitant within or surrounding
designated clusters to participate. This will be
accounted for in the final interpretation of study re-
sults. The risks of transmission from unenrolled per-
sons in the area will also be assessed by study team
members during the trial (e.g., by documenting how
many persons in a given area do not enroll) so as to
incorporate into the final analysis to the best of our
abilities.
Analysis of the effectiveness of MMP versus FSAT is the
primary intervention (and outcome) of interest based on
absolute risk reduction at 24 weeks. While the MMP arm
reverts to standard-of-care (e.g., FSAT) after the 12-week
intervention period, it would be unethical to not treat
study participants who suffer new malaria infections dur-
ing the follow-up period. This is intended to simulate a
likely elimination program where an intervention is tried,
and then the community defaults to standard of care while
it is monitored afterward to determine effectiveness.
While there is the potential for overlap between groups
due to treatment during the follow-up period, the hypoth-
esis is that the more intensive MMP intervention will re-
duce overall risk of disease further than the less intensive
FSAT approach in the allotted study window. While we
also wish to assess any additive effects of permethrin-
treated clothing over pharmacological interventions in the
treated clusters, the study is not powered based on per-
methrin treatment. In addition to estimation of additive
effects, the intervention was performed to assess feasibility
to effectively implement permethrin treatment and deter-
mine adherence to clothing wear.
It is anticipated and often argued that the large effort re-
quired to effectively achieve malaria elimination will pre-
clude medical and safety monitoring. The feasibility of this
approach will be assessed through analysis of diagnostic
and adverse event data. If determined that elimination ob-
jectives could not be met without the intensity of medical
monitoring to be employed here, it is possible that the
study may conclude that approaches to malaria elimin-
ation studied here are not currently feasible. Technical,
organizational and/or resource constraints may favor a
more gradual approach as patient safety must always re-
main a paramount consideration. Regardless of outcomes,
this initial study will serve as a pilot for scale-up efforts,
and inform future operational approaches. Lastly, in an ef-
fort to optimize safety, due to phlebotomy limits for youn-
ger children, pediatric volunteers aged less than 13 years
will not be screened for G6PD deficiency and will not re-
ceive PQ. While not expected based on known demo-
graphics of military dependents living along Cambodia’s
borders, higher than anticipated pediatric enrollment
could limit the study’s ability to discern potential benefits
of the selected PQ dose.
Translating results into action
As Cambodia approaches its stated goal of P. falciparum
malaria elimination by 2020, and all malaria eliminated
by 2025, a multitude of research efforts are underway to
develop best practices. While mathematical models
provide some guidance, evidence from randomized
controlled trials on the most effective practical interven-
tions for elimination is lacking. To date, most trials of
mass drug administration have been historical, poorly de-
signed, non-randomized or controlled [48]. Use of malaria
prophylaxis has rarely been a stated objective of such
studies beyond the secondary effects of mass
treatment. The study will provide essential evidence
to formulate a national elimination strategy serving
vulnerable mobile populations who remain reservoirs
for malaria transmission, comparing a large-scale pre-
vention approach with current efforts to screen and
treat individuals. At the same time, the study will
strengthen the RCAF’s ability to pursue malaria elim-
ination by strengthening surveillance capacity, man-
aging information systems, and improving the quality
of care. Ultimately the study will inform the Cambo-
dian Government and other stakeholders regarding a
practical approach to elimination in an underserved
but critically important population.
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